Table 1.
Antibody-drug conjugates approved by the FDA.
| Generic Name | Brand Name (Manufacturer) |
Indication | Approval Year | ADC Characteristics | |||
|---|---|---|---|---|---|---|---|
| Antibody Isotype | Target Antigen |
Linker | Payload | ||||
| Brentuximab vedotin |
Adcetris (Seattle Genetics) |
HL, ALCL | 2011 | IgG1 | CD30 | Cleavable (protease) |
MMAE |
| Ado-trastuzumab emtasine |
Kadcyla (Genentech) |
HER2+ mBC HER2+ eBC |
2013 | IgG1 | HER2 | Non-cleavable | DM1 |
| Inotuzumab ozogamicin |
Besponsa (Pfizer) |
ALL | 2017 | IgG4 | CD22 | Cleavable (acid labile) |
Calicheamicin |
| Gemtuzumab ozogamicin |
Mylotarg (Pfizer) |
CD33+ AML | 2017 | IgG4 | CD33 | Cleavable (disulfide) |
Calicheamicin |
| Moxetumomab pasudotox-tdfk |
Lumoxiti (AstraZeneca) |
r/r HCL | 2018 | IgG1 | CD22 | Cleavable (disulfide) |
Pseudomonas exotoxin |
| Polatuzumab vedotin |
Polivy (Genentech) |
r/r DLBCL | 2019 | IgG1 | CD79b | Cleavable (protease) |
MMAE |
| Enfortumab vedotin |
Padcev (Seattle Genetics) |
mUC | 2019 | IgG1 | Nectin-4 | Cleavable (protease) |
MMAE |
| Trastuzumab deruxtecan | Enhertu (AstraZeneca) (Daiichi-Sankyo) |
HER2+ BC HER2+ GC/GEJ |
2019 | IgG1 | HER2 | Cleavable (peptides) |
DXd |
| Sacituzumab govitecan | Trodelvy (Imunomedics) |
mTNBC | 2020 | IgG1 | Trop-2 | Cleavable (acid labile) |
SN-38 |
| Belantamab mafodotin-blmf | Blenrep (GlaxoSmithKline) |
Multiple myeloma |
2020 | IgG1 | BCMA | Cleavable (protease) |
MMAF |
Abbreviations: ALCL, aplastic large cell lymphoma; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BC, breast cancer; DLBCL, diffuse large B cell lymphoma; DM1, mertansine; Dxd, topoisomerase I inhibitor; eBC, early breast cancer; GC, gastric cancer; GEJ, gastroesophogeal junction adenocarcinoma; HCL, hairy cell lymphoma; HL, Hodgkin lymphoma; mBC, metastatic breast cancer; mc, maleimidocaproyl; MMAE, monomethyl auristatin E; MMAF, monomethyl auristatin F; mTNBC, metastatic triple-negative breast cacner; mUC, metastatic urothelial cancer; r/r, relapsed/refractory; SN-38, active metabolite of irinotecan.